ArticleInternational journal of women's health2025
Efficacy and Safety Comparisons of Lingshu Granule versus Decoction in Polycystic Ovary Syndrome Patients with Insulin Resistance: A Multicenter Randomized Controlled Dose-Finding Trial Protocol.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. Although multiple treatment strategies have been proposed, many patients still experience suboptimal outcomes. Our research team has developed the Lingshu formula, which is grounded in traditional Chinese medicine theory, focusing on kidney deficiency and phlegm dampness. Clinical and animal studies have demonstrated its efficacy in improving insulin resistance, regulating hormonal and lipid metabolism, and reducing obesity, which was non-inferior to metformin. However, Lingshu is traditionally prepared in formula decoction, with a complicated and time-consuming process. The granule preparations have offered the advantages of stable drug quality, convenient storage and administration, and high patient compliance. However, the efficacy, safety, and optimal dosage of the Lingshu formula granules compared to its traditional decoction in the treatment of PCOS patients with insulin resistance still require further investigation. Therefore, this study aims to determine whether the Lingshu formula granules are superior to the traditional decoction and to establish their optimal dosage. Methods: We will conduct a multicenter, randomized, controlled clinical trial targeted to enroll 200 patients. Eligible participants will be randomly assigned, in a 1:1:1:1 ratio, to group A (low-dose Lingshu granules, -20% from standard dose), group B (medium-dose Lingshu granules, standard dose), group C (high-dose Lingshu granules, +20% from standard dose), or group D (Lingshu decoction). Treatment will last 90 days. The primary outcome is the insulin resistance index, and secondary outcomes include body mass index, waist-to-hip ratio, and laboratory tests, which will be recorded and compared across these four groups. In addition, variations in symptoms related to the Chinese traditional medicine and adverse events will also be documented and compared. Discussion: The findings are expected to provide a scientific basis for the clinical application of the Lingshu formula granules in PCOS patients with insulin resistance and promote widespread use of traditional Chinese medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.